Recombinant proteins are an indispensable tool in drug discovery. The need for multiple forms of recombinant proteins, e.g. wild/mutant/fusion, from different species is increasing and we seek to fulfill the demand providing excellent service and support. (more…)

Screening by MS becomes more and more popular to cover expanding demand in novel research areas in scientific world. Screening by MS includes several approaches with different areas of application which are essential for drug-discovery research. (more…)

New Technology Department was established as a natural expansion of Bienta and currently provides services for Recombinant Proteins Production and Screening by Mass Spectrometry.

The Screening Group provides hit identification and hit-to-lead optimization contract services to the biotech and pharmaceutical industry. We are also open to discuss shared-risk exploratory hit finding projects with the industry or academic partners… (more…)

The growing Bienta currently employs 83 FTEs and is capable of performing HTS with a broad variety of biochemical and cell-based assays. (more…)

Our Molecular Modeling group provides cheminformatics, molecular modeling, virtual screening and computational biology services aiming to accelerate hit identification, lead generation and lead optimization stages of the drug discovery process… (more…)